Paper29545809
The Autoimmune Skin Disease Bullous Pemphigoid: The Role of Mast Cells in Autoantibody-Induced Tissue Injury.
Fang H and 4 others. Front Immunol, 2018. Cited by 35 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. The Autoimmune Skin Disease Bullous Pemphigoid: The Role of Mast Cells in Autoantibody-Induced Tissue Injury. Papers, record 29545809. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29545809
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Autoantibodies | Major topic |
| Autoimmune Diseases | Major topic |
| Mast Cells | Major topic |
| Pemphigoid, Bullous | Major topic |
| Skin | Major topic |
| Animals | |
| Antibody-Dependent Cell Cytotoxicity | |
| Autoantigens | |
| Disease Models, Animal | |
| Humans | |
| Non-Fibrillar Collagens | |
| Collagen Type XVII |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 AI040768 | NIAID NIH HHS | United States | R01AI040768 | PubMed and NIH | NIH RePORTER |
| R01 AR070276 | NIAMS NIH HHS | United States | R01AR070276 | PubMed and NIH | NIH RePORTER |
References112
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23,237,497 | Pemphigoid diseases. | Lancet | 2013 | https://conductscience.org/library/papers/23237497 | PubMed |
| 2 | 25,678,008 | Conditional depletion of mast cells has no impact on the severity of experimental epidermolysis bullosa acquisita. | Eur J Immunol | 2015 | https://conductscience.org/library/papers/25678008 | PubMed |
| 3 | 1,698,819 | Isolation of a human epidermal cDNA corresponding to the 180-kD autoantigen recognized by bullous pemphigoid and herpes gestationis sera. Immunolocalization of this protein to the hemidesmosome. | J Clin Invest | 1990 | https://conductscience.org/library/papers/1698819 | PubMed |
| 4 | 7,035,575 | Bullous pemphigoid, an ultrastructural study of the inflammatory response: eosinophil, basophil and mast cell granule changes in multiple biopsies from one patient. | J Invest Dermatol | 1982 | https://conductscience.org/library/papers/7035575 | PubMed |
| 5 | 1,107,422 | An eosinophil chemotactic factor present in blister fluids of bullous pemphigoid patients. | J Immunol | 1976 | https://conductscience.org/library/papers/1107422 | PubMed |
| 6 | 12,900,518 | The chymase, mouse mast cell protease 4, constitutes the major chymotrypsin-like activity in peritoneum and ear tissue. A role for mouse mast cell protease 4 in thrombin regulation and fibronectin turnover. | J Exp Med | 2003 | https://conductscience.org/library/papers/12900518 | PubMed |
| 7 | 9,747,382 | The association of HLA-DQ7 with bullous pemphigoid is restricted to men. | Br J Dermatol | 1998 | https://conductscience.org/library/papers/9747382 | PubMed |
| 8 | 24,434,029 | Update on the pathogenesis of bullous pemphigoid: an autoantibody-mediated blistering disease targeting collagen XVII. | J Dermatol Sci | 2014 | https://conductscience.org/library/papers/24434029 | PubMed |
| 9 | 2,229,408 | Identification of IgE-positive cells and mast cells in frozen sections of multiple sclerosis brains. | J Neuroimmunol | 1990 | https://conductscience.org/library/papers/2229408 | PubMed |
| 10 | 16,543,893 | Induction of epidermolysis bullosa acquisita in mice by passive transfer of autoantibodies from patients. | J Invest Dermatol | 2006 | https://conductscience.org/library/papers/16543893 | PubMed |
| 11 | 18,483,499 | Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. | Nat Rev Immunol | 2008 | https://conductscience.org/library/papers/18483499 | PubMed |
| 12 | 8,642,104 | Elevated levels of interleukin-8 in blister fluid of bullous pemphigoid compared with suction blisters of healthy control subjects. | J Am Acad Dermatol | 1996 | https://conductscience.org/library/papers/8642104 | PubMed |
| 13 | 24,925,389 | Urticaria and angioedema. | Chem Immunol Allergy | 2014 | https://conductscience.org/library/papers/24925389 | PubMed |
| 14 | 17,475,881 | The alternative pathway of complement activation is critical for blister induction in experimental epidermolysis bullosa acquisita. | J Immunol | 2007 | https://conductscience.org/library/papers/17475881 | PubMed |
| 15 | 1,444,583 | Increased immunoreactive interleukin-5 levels in blister fluids of bullous pemphigoid. | Arch Dermatol Res | 1992 | https://conductscience.org/library/papers/1444583 | PubMed |
| 16 | 15,175,032 | BP230- and BP180-specific auto-antibodies in bullous pemphigoid. | J Invest Dermatol | 2004 | https://conductscience.org/library/papers/15175032 | PubMed |
| 17 | 340,950 | Morphologic and functional evidence for release of mast-cell products in bullous pemphigoid. | N Engl J Med | 1978 | https://conductscience.org/library/papers/340950 | PubMed |
| 18 | 24,845,463 | Unraveling the significance of IgE autoantibodies in organ-specific autoimmunity: lessons learned from bullous pemphigoid. | Immunol Res | 2014 | https://conductscience.org/library/papers/24845463 | PubMed |
| 19 | 17,681,377 | The extended cleavage specificity of the rodent beta-chymases rMCP-1 and mMCP-4 reveal major functional similarities to the human mast cell chymase. | Mol Immunol | 2008 | https://conductscience.org/library/papers/17681377 | PubMed |
| 20 | 24,954,907 | Omalizumab therapy for bullous pemphigoid. | J Am Acad Dermatol | 2014 | https://conductscience.org/library/papers/24954907 | PubMed |
Cited by24
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 35 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,502,352 | Mendelian Randomization and Experimental Validation Identify Key Immune Signatures in Bullous Pemphigoid. | Clin Cosmet Investig Dermatol | 2026 | https://conductscience.org/library/papers/42502352 | PubMed |
| 42,094,004 | Regulatory T cells in bullous pemphigoid: biological characteristics, dysfunction, and pathogenic roles. | Front Immunol | 2026 | https://conductscience.org/library/papers/42094004 | PubMed |
| 41,909,698 | Tyrosine kinase signaling pathways as therapeutic targets in autoimmune subepidermal blistering skin diseases (pemphigoid diseases). | Front Immunol | 2026 | https://conductscience.org/library/papers/41909698 | PubMed |
| 40,758,112 | Vildagliptin and its Association with Bullous Pemphigoid. | Ann Afr Med | 2026 | https://conductscience.org/library/papers/40758112 | PubMed |
| 40,289,982 | Advanced Glycation End Products and Skin Autoimmune Disorders: Pathogenic Insights into Vitiligo, Bullous Pemphigoid, and Type 1 Diabetes Mellitus. | Curr Med Chem | 2025 | https://conductscience.org/library/papers/40289982 | PubMed |
| 39,979,318 | Bullous pemphigoid. | Nat Rev Dis Primers | 2025 | https://conductscience.org/library/papers/39979318 | PubMed |
| 39,459,488 | Factors Influencing the Clinical Course of Bullous Pemphigoid among Geriatric Patients: A Pilot Study. | Medicina (Kaunas) | 2024 | https://conductscience.org/library/papers/39459488 | PubMed |
| 39,425,892 | Pathophysiology of Bullous Pemphigoid: Role of Type 2 Inflammation and Emerging Treatment Strategies (Narrative Review). | Adv Ther | 2024 | https://conductscience.org/library/papers/39425892 | PubMed |
| 38,069,109 | From Molecular Insights to Clinical Perspectives in Drug-Associated Bullous Pemphigoid. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/38069109 | PubMed |
| 37,853,878 | Refractory Bullous Pemphigoid Successfully Treated with Reslizumab: A Possible Novel Therapeutic Modality. | Ann Dermatol | 2023 | https://conductscience.org/library/papers/37853878 | PubMed |
| 37,575,240 | Dupilumab effectively and rapidly treats bullous pemphigoid by inhibiting the activities of multiple cell types. | Front Immunol | 2023 | https://conductscience.org/library/papers/37575240 | PubMed |
| 36,993,969 | Adaptive and innate immune pathogenesis of bullous pemphigoid: A review. | Front Immunol | 2023 | https://conductscience.org/library/papers/36993969 | PubMed |
| 36,685,586 | A case report of steroid-refractory bullous pemphigoid induced by immune checkpoint inhibitor therapy. | Front Immunol | 2022 | https://conductscience.org/library/papers/36685586 | PubMed |
| 34,504,496 | Emerging Biomarkers and Therapeutic Strategies for Refractory Bullous Pemphigoid. | Front Immunol | 2021 | https://conductscience.org/library/papers/34504496 | PubMed |
| 34,360,845 | Mast Cell Cytokines IL-1, IL-33, and IL-36 Mediate Skin Inflammation in Psoriasis: A Novel Therapeutic Approach with the Anti-Inflammatory Cytokines IL-37, IL-38, and IL-1Ra. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34360845 | PubMed |
| 32,163,298 | Factors associated with the activity and severity of bullous pemphigoid: a review. | Ann Med | 2020 | https://conductscience.org/library/papers/32163298 | PubMed |
| 31,749,790 | Genetics and Omics Analysis of Autoimmune Skin Blistering Diseases. | Front Immunol | 2019 | https://conductscience.org/library/papers/31749790 | PubMed |
| 31,312,206 | New Insights Into the Pathogenesis of Bullous Pemphigoid: 2019 Update. | Front Immunol | 2019 | https://conductscience.org/library/papers/31312206 | PubMed |
| 31,297,118 | Proteases in Pemphigoid Diseases. | Front Immunol | 2019 | https://conductscience.org/library/papers/31297118 | PubMed |
| 31,281,316 | Role of the Pruritic Cytokine IL-31 in Autoimmune Skin Diseases. | Front Immunol | 2019 | https://conductscience.org/library/papers/31281316 | PubMed |
Genes34
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29545809
GET https://conductscience.org/api/papers/v1/29545809/references?page=2